BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2777 related articles for article (PubMed ID: 24178005)

  • 1. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
    Li TS; Yawata T; Honke K
    Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth.
    Liu XQ; Xiong MH; Shu XT; Tang RZ; Wang J
    Mol Pharm; 2012 Oct; 9(10):2863-74. PubMed ID: 22924580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
    Hadinoto K; Sundaresan A; Cheow WS
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PEGylated carboxymethyl chitosan/calcium phosphate hybrid anionic nanoparticles mediated hTERT siRNA delivery for anticancer therapy.
    Xie Y; Qiao H; Su Z; Chen M; Ping Q; Sun M
    Biomaterials; 2014 Sep; 35(27):7978-91. PubMed ID: 24939077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes.
    Gu J; Al-Bayati K; Ho EA
    Drug Deliv Transl Res; 2017 Aug; 7(4):497-506. PubMed ID: 28315051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ionically crosslinked Ad/chitosan nanocomplexes processed by electrospinning for targeted cancer gene therapy.
    Park Y; Kang E; Kwon OJ; Hwang T; Park H; Lee JM; Kim JH; Yun CO
    J Control Release; 2010 Nov; 148(1):75-82. PubMed ID: 20637814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic targeting of chitosan-PEG-folate-complexed oncolytic adenovirus for active and systemic cancer gene therapy.
    Kwon OJ; Kang E; Choi JW; Kim SW; Yun CO
    J Control Release; 2013 Aug; 169(3):257-65. PubMed ID: 23562633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folate mediated histidine derivative of quaternised chitosan as a gene delivery vector.
    Morris VB; Sharma CP
    Int J Pharm; 2010 Apr; 389(1-2):176-85. PubMed ID: 20117198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folate mediated in vitro targeting of depolymerised trimethylated chitosan having arginine functionality.
    Morris VB; Sharma CP
    J Colloid Interface Sci; 2010 Aug; 348(2):360-8. PubMed ID: 20580766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery.
    Tian Q; Zhang CN; Wang XH; Wang W; Huang W; Cha RT; Wang CH; Yuan Z; Liu M; Wan HY; Tang H
    Biomaterials; 2010 Jun; 31(17):4748-56. PubMed ID: 20303163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular siRNA delivery dynamics of integrin-targeted, PEGylated chitosan-poly(ethylene imine) hybrid nanoparticles: A mechanistic insight.
    Ragelle H; Colombo S; Pourcelle V; Vanvarenberg K; Vandermeulen G; Bouzin C; Marchand-Brynaert J; Feron O; Foged C; Préat V
    J Control Release; 2015 Aug; 211():1-9. PubMed ID: 25989603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting CD146 using folic acid-conjugated nanoparticles and suppression of tumor growth in a mouse glioma model.
    Fukui N; Yawata T; Nakajo T; Kawanishi Y; Higashi Y; Yamashita T; Aratake T; Honke K; Ueba T
    J Neurosurg; 2020 Jul; 134(6):1772-1782. PubMed ID: 32707539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of poly(ethylene glycol) grafting density on the tumor targeting efficacy of nanoparticles with ligand modification.
    Zhang S; Tang C; Yin C
    Drug Deliv; 2015 Feb; 22(2):182-90. PubMed ID: 24215373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutathione-sensitive RGD-poly(ethylene glycol)-SS-polyethylenimine for intracranial glioblastoma targeted gene delivery.
    Lei Y; Wang J; Xie C; Wagner E; Lu W; Li Y; Wei X; Dong J; Liu M
    J Gene Med; 2013; 15(8-9):291-305. PubMed ID: 24038955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts.
    Yoshizawa T; Hattori Y; Hakoshima M; Koga K; Maitani Y
    Eur J Pharm Biopharm; 2008 Nov; 70(3):718-25. PubMed ID: 18647651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Core-shell type lipid/rPAA-Chol polymer hybrid nanoparticles for in vivo siRNA delivery.
    Gao LY; Liu XY; Chen CJ; Wang JC; Feng Q; Yu MZ; Ma XF; Pei XW; Niu YJ; Qiu C; Pang WH; Zhang Q
    Biomaterials; 2014 Feb; 35(6):2066-78. PubMed ID: 24315577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dodecanol-poly(D,L-lactic acid)-b-poly (ethylene glycol)-folate (Dol-PLA-PEG-FA) nanoparticles: evaluation of cell cytotoxicity and selecting capability in vitro.
    Wang S; Luo Y; Zeng S; Luo C; Yang L; Liang Z; Wang Y
    Colloids Surf B Biointerfaces; 2013 Feb; 102():130-5. PubMed ID: 23000678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytocompatible chitosan-graft-mPEG-based 5-fluorouracil-loaded polymeric nanoparticles for tumor-targeted drug delivery.
    Antoniraj MG; Ayyavu M; Henry LJK; Nageshwar Rao G; Natesan S; Sundar DS; Kandasamy R
    Drug Dev Ind Pharm; 2018 Mar; 44(3):365-376. PubMed ID: 28835136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chitosan nanoparticles for siRNA delivery: optimizing formulation to increase stability and efficiency.
    Ragelle H; Riva R; Vandermeulen G; Naeye B; Pourcelle V; Le Duff CS; D'Haese C; Nysten B; Braeckmans K; De Smedt SC; Jérôme C; Préat V
    J Control Release; 2014 Feb; 176():54-63. PubMed ID: 24389132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific targeting of cancer cells by multifunctional mitoxantrone-conjugated magnetic nanoparticles.
    Heidari Majd M; Asgari D; Barar J; Valizadeh H; Kafil V; Coukos G; Omidi Y
    J Drug Target; 2013 May; 21(4):328-40. PubMed ID: 23293842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 139.